Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Evan Y. Yu"'
Autor:
Tessa Ladner, Anna J. Black, Homayoun Zargar, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Michael S. Cookson, Niels-Erik Jacobsen, Adrian S. Fairey, Colin P. N. Dinney, Maria C. Mir, Laura-Maria Krabbe, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Andrew J. Stephenson, Jay B. Shah, Siamak Daneshmand, Kamran Zargar-Shoshtari, Philippe E. Spiess, Laura S. Mertens, Bas W. G. van Rhijn, Petros Grivas, Wassim Kassouf, Marc A. Dall’Era, Srikala S. Sridhar, Jonathan S. McGrath, Jonathan Aning, Shahrokh F. Shariat, Trinity J. Bivalacqua, Scott A. North, Daniel A. Barocas, Yair Lotan, Peter C. Black
Publikováno v:
Société Internationale d’Urologie Journal, Vol 5, Iss 3, Pp 202-213 (2024)
Objectives: Perioperative blood transfusion (PBT) has been associated with worse survival after radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC). Here, we evaluated the association between PBT and survival after RC that
Externí odkaz:
https://doaj.org/article/014c07b617934d568005c539c0294ffb
Autor:
Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian Hanratty, Mohamed Adil, Jimmy Zhao, Samir Zaidi, Lawrence D. True, Jamie M. Sperger, Heather H. Cheng, Evan Y. Yu, Robert B. Montgomery, Jessica E. Hawley, Gavin Ha, Thomas Persse, Patricia Galipeau, John K. Lee, Stephanie A. Harmon, Eva Corey, Joshua M. Lang, Charles L. Sawyers, Colm Morrissey, Michael T. Schweizer, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the ex
Externí odkaz:
https://doaj.org/article/cdd085eaf0e84556a25f843f3b873e3c
Autor:
Mark Muzi, Finbarr O’Sullivan, Timothy G. Perk, John P. Muzi, David A. Mankoff, Robert Jeraj, Fenghai Duan, Evan Y. Yu
Publikováno v:
Tomography, Vol 7, Iss 2, Pp 139-153 (2021)
ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [18F]-fluoride (NaF) PET imaging. We extend previous ACRIN 6687 dynam
Externí odkaz:
https://doaj.org/article/b6553ee71bf24e44a64e800a87f20f22
Autor:
Matthew D. Greer, MD, Stephanie K. Schaub, MD, Stephen R. Bowen, PhD, Jay J. Liao, MD, Kenneth Russell, MD, Jonathan J. Chen, MD, Emily S. Weg, MD, Juergen Meyer, PhD, Tristan Alving, George R. Schade, MD, John L. Gore, MD, Sarah P. Psutka, MD, MS, Robert B. Montgomery, MD, Michael Schweizer, MD, Evan Y. Yu, MD, Petros Grivas, MD, PhD, Jonathan L. Wright, MD, MS, FACS, Jing Zeng, MD
Publikováno v:
Advances in Radiation Oncology, Vol 7, Iss 2, Pp 100858- (2022)
Purpose: We conducted a prospective pilot study to evaluate safety and feasibility of TraceIT, a resorbable radiopaque hydrogel, to improve image guidance for bladder cancer radiation therapy (RT). Methods and Materials: Patients with muscle invasive
Externí odkaz:
https://doaj.org/article/db65bfdaad0242839436f021308da4cd
Autor:
Alexander S. Carlson, Rigo I. Acevedo, Daniel M. Lim, Roman Gulati, Agnes Gawne, Alexandra O. Sokolova, Heather H. Cheng, Peter S. Nelson, R. Bruce Montgomery, Evan Y. Yu, Michael T. Schweizer, Alvaro Galli
Publikováno v:
PLoS ONE, Vol 15, Iss 9 (2020)
Introduction A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibilit
Externí odkaz:
https://doaj.org/article/5ed7e474f7d94fa08efcaadf52519db1
Autor:
Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R. Plimack, Lauren C. Harshman, Evan Y. Yu, Simon J. Crabb, Sumanta Kumar Pal, Ajjai S. Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N. Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D. Galsky, Cora N. Sternberg
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Background: MIBC is an aggressive disease, with 5-year survival rates ranging from 36 to 48% for p T3/p T4/p N+tumors. Perioperative treatment can improve overall survival, with more robust evidence in favor of neoadjuvant chemotherapy. Few randomize
Externí odkaz:
https://doaj.org/article/07c29ee921bc45cdbbe4ef5cab278458
Autor:
Michael T. Schweizer, Evan Y. Yu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 8 (2016)
While initially effective, androgen deprivation therapy (ADT) is not curative, and nearly all men with advanced prostate cancer will eventually progress to the more resistant, and ultimately lethal form of the disease, so called castration-resistant
Externí odkaz:
https://doaj.org/article/ba4c712c65c5485fbedf171a949b750c
Autor:
Michael T. Schweizer, Evan Y. Yu
Publikováno v:
Cancers, Vol 9, Iss 1, p 7 (2017)
In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past
Externí odkaz:
https://doaj.org/article/27f1d160446d49e785e4f74ecf04d3b8
Autor:
Franklin C. Lee, William Harris, Heather H. Cheng, Jaideep Shenoi, Song Zhao, Junfeng Wang, Thomas Champion, Jason Izard, John L. Gore, Michael Porter, Evan Y. Yu, Jonathan L. Wright
Publikováno v:
Advances in Urology, Vol 2013 (2013)
Objectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods. Data was retrospectively collected on 178 patients
Externí odkaz:
https://doaj.org/article/385a4c3c44ac4e0883ebe1425ce84c4b
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
While checkpoint inhibitor therapy has revolutionized the treatment landscape of some solid tumors, it has shown limited efficacy in metastatic castration-resistant prostate cancers (mCRPC). A small (~3–5%) but clinically distinct subset of mCRPC t
Externí odkaz:
https://doaj.org/article/bed81baf87404fb88900da554fc861d6